U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07404332) titled '5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors' on Feb. 04.
Brief Summary: This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Locally Advanced Solid Tumor
Metastatic Tumor
Intervention:
DRUG: 5 Azacytidine
5-Azacitidine (Azacitidine) is a nucleoside analogue chemotherapy drug
DRUG: Pembrolizumab
Pembrolizumab is a high-affinity humanized mo...